Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Zymeworks (ZYME) Financials

Zymeworks logo
$25.35 +0.51 (+2.07%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Zymeworks

Annual Income Statements for Zymeworks

This table shows Zymeworks' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -181 -212 124 -119 -123 -80
Consolidated Net Income / (Loss)		 -181 -212 124 -119 -123 -81
Net Income / (Loss) Continuing Operations		 -181 -212 124 -119 -123 -81
Total Pre-Tax Income 		-180 -212 135 -119 -117 -80
Total Operating Income		 -187 -216 131 -138 -137 -93
Total Gross Profit		 39 27 412 76 76 106
Total Revenue		 39 27 412 76 76 106
Operating Revenue		 39 27 412 76 76 106
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 226 242 282 214 213 199
Selling, General & Admin Expense		 55 43 73 70 62 62
Research & Development Expense		 171 200 209 144 135 137
Impairment Charge		 - - 0.00 0.00 17 0.00
Total Other Income / (Expense), net		 7.35 3.27 4.71 19 20 13
Interest & Investment Income		 5.70 1.97 3.60 20 20 13
Other Income / (Expense), net		 1.65 1.31 1.11 -0.89 0.56 -0.56
Income Tax Expense		 0.43 -0.52 11 -0.57 6.08 1.38
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - 0.00 - -0.06 0.35 -0.87
Basic Earnings per Share		 ($3.58) ($4.11) $1.91 ($1.72) ($1.62) ($1.08)
Weighted Average Basic Shares Outstanding		 50.38M 51.55M 65.19M 68.86M 75.85M 75.40M
Diluted Earnings per Share		 ($3.58) ($4.61) $1.90 ($1.72) ($1.62) ($1.08)
Weighted Average Diluted Shares Outstanding		 50.38M 52.13M 65.25M 68.86M 75.88M 75.41M
Weighted Average Basic & Diluted Shares Outstanding		 - - 64.04M 70.57M 69.58M 73.75M

Quarterly Income Statements for Zymeworks

This table shows Zymeworks' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -29 -13 -33 -38 -30 -24 -23 2.32 -20 -41 -44
Consolidated Net Income / (Loss)		 -29 -14 -32 -38 -30 -24 -23 2.32 -20 -41 -44
Net Income / (Loss) Continuing Operations		 -29 -14 -32 -38 -30 -24 -23 2.32 -20 -41 -44
Total Pre-Tax Income 		-28 -19 -32 -38 -30 -18 -22 2.13 -18 -41 -46
Total Operating Income		 -33 -23 -38 -43 -34 -22 -26 -0.67 -22 -44 -47
Total Gross Profit		 17 17 10 19 16 31 27 49 28 2.52 2.41
Total Revenue		 17 17 10 19 16 31 27 49 28 2.52 2.41
Operating Revenue		 17 17 10 19 16 31 27 49 28 2.52 2.41
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 50 40 48 62 50 53 53 49 50 47 50
Selling, General & Admin Expense		 17 15 16 16 14 16 17 15 14 15 15
Research & Development Expense		 33 26 32 46 36 20 36 34 36 31 34
Total Other Income / (Expense), net		 5.66 4.22 6.22 5.27 4.58 4.43 3.47 2.81 3.84 2.67 0.77
Interest Expense		 - - - - - - 0.00 - - - 2.07
Interest & Investment Income		 5.03 5.05 5.92 5.15 4.79 4.08 3.42 3.43 3.53 2.98 2.71
Other Income / (Expense), net		 0.63 -0.83 0.30 0.11 -0.20 0.34 0.05 -0.62 0.32 -0.30 0.12
Income Tax Expense		 1.11 -4.72 0.08 0.07 0.23 5.72 0.50 -0.19 1.34 -0.27 -2.19
Basic Earnings per Share		 ($0.41) ($0.19) ($0.42) ($0.49) ($0.39) ($0.32) ($0.30) $0.03 ($0.26) ($0.55) ($0.59)
Weighted Average Basic Shares Outstanding		 70.58M 68.86M 76.21M 76.39M 76.13M 75.85M 75.17M 75.34M 75.77M 75.40M 74.67M
Diluted Earnings per Share		 ($0.41) ($0.18) ($0.42) ($0.49) ($0.39) ($0.32) ($0.30) $0.03 ($0.26) ($0.55) ($0.59)
Weighted Average Diluted Shares Outstanding		 70.58M 68.86M 76.25M 76.40M 76.16M 75.88M 75.23M 77.38M 75.78M 75.41M 74.69M
Weighted Average Basic & Diluted Shares Outstanding		 70.00M 70.57M 70.70M 71.05M 68.88M 69.58M 69.68M 75.17M 74.84M 73.75M 73.02M

Annual Cash Flow Statements for Zymeworks

This table details how cash moves in and out of Zymeworks' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 114 -40 199 -243 -91 -25
Net Cash From Operating Activities		 -151 -192 144 -118 -110 -33
Net Cash From Continuing Operating Activities		 -151 -192 144 -118 -110 -33
Net Income / (Loss) Continuing Operations		 -181 -212 124 -119 -123 -81
Consolidated Net Income / (Loss)		 -181 -212 124 -119 -123 -81
Depreciation Expense		 3.36 3.74 6.22 7.46 4.19 3.67
Amortization Expense		 6.92 5.84 5.78 9.84 7.01 7.44
Non-Cash Adjustments To Reconcile Net Income		 29 10 2.06 8.74 34 29
Changes in Operating Assets and Liabilities, net		 -9.58 -0.35 5.71 -26 -32 8.45
Net Cash From Investing Activities		 -43 145 -54 -207 39 27
Net Cash From Continuing Investing Activities		 -43 145 -54 -207 39 27
Purchase of Property, Plant & Equipment		 -4.31 -12 -8.15 -2.47 -1.99 -1.52
Acquisitions		 -1.96 -0.88 -4.98 -1.60 -1.08 -0.83
Purchase of Investments		 -37 -35 -113 -553 -284 -196
Sale and/or Maturity of Investments		 - 193 72 350 326 225
Net Cash From Financing Activities		 309 8.01 109 82 -20 -19
Net Cash From Continuing Financing Activities		 308 8.01 109 82 -20 -19
Repurchase of Common Equity		 - - 0.00 0.00 -30 -42
Issuance of Common Equity		 308 8.50 109 82 9.79 23
Other Financing Activities, net		 -0.04 -0.49 -0.61 -0.05 -0.17 -0.18
Effect of Exchange Rate Changes		 -0.55 -0.33 0.20 0.35 0.29 -0.05
Cash Income Taxes Paid		 - - 10 0.17 3.18 1.35

Quarterly Cash Flow Statements for Zymeworks

This table details how cash moves in and out of Zymeworks' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -48 63 -43 -44 51 -56 10 22 -33 -24 203
Net Cash From Operating Activities		 -43 14 -38 -25 -5.88 -42 -3.41 12 -31 -10 -46
Net Cash From Continuing Operating Activities		 -43 14 -38 -25 -5.88 -42 -3.41 12 -31 -10 -46
Net Income / (Loss) Continuing Operations		 -29 -14 -32 -38 -30 -24 -23 2.32 -20 -41 -44
Consolidated Net Income / (Loss)		 -29 -14 -32 -38 -30 -24 -23 2.32 -20 -41 -44
Depreciation Expense		 2.40 1.54 1.06 1.10 1.04 1.00 0.98 0.89 0.91 0.90 0.96
Amortization Expense		 4.14 1.81 1.25 1.43 1.63 2.69 2.32 2.33 1.68 1.11 1.91
Non-Cash Adjustments To Reconcile Net Income		 1.52 4.39 3.07 22 4.80 4.13 6.37 6.58 6.46 9.16 8.64
Changes in Operating Assets and Liabilities, net		 -22 21 -11 -11 17 -26 9.55 -0.04 -21 20 -13
Net Cash From Investing Activities		 -7.02 -1.34 -7.32 -20 72 -6.21 12 8.75 0.37 5.37 70
Net Cash From Continuing Investing Activities		 -7.02 -1.34 -7.32 -20 72 -6.21 12 8.75 0.37 5.37 70
Purchase of Property, Plant & Equipment		 -0.93 -0.36 -0.19 -0.59 -0.90 -0.31 -0.02 -0.51 -0.41 -0.58 -0.22
Acquisitions		 -0.21 -1.40 -0.47 -0.50 -0.10 - -0.32 -0.37 - -0.14 0.00
Purchase of Investments		 -125 -62 -67 -111 -53 -54 -34 -70 -35 -57 0.00
Sale and/or Maturity of Investments		 119 62 60 92 126 48 47 80 36 63 70
Net Cash From Financing Activities		 1.90 51 2.13 1.05 -15 -8.64 1.32 1.32 -2.45 -19 179
Net Cash From Continuing Financing Activities		 1.90 51 2.13 1.05 -15 -8.64 1.32 1.32 -2.45 -19 179
Repurchase of Common Equity		 - - - - - -9.43 0.00 - - -25 -76
Issuance of Common Equity		 1.91 51 2.13 1.13 5.74 0.79 1.32 1.38 14 6.83 9.32
Other Financing Activities, net		 -0.02 -0.02 - -0.09 -0.10 -0.00 0.00 - - - 246
Effect of Exchange Rate Changes		 0.02 -0.00 0.12 0.06 -0.01 0.11 0.01 -0.09 0.08 -0.04 0.10
Cash Income Taxes Paid		 - - 0.00 - - - 0.39 0.20 0.66 0.11 0.25

Annual Balance Sheets for Zymeworks

This table presents Zymeworks' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 389 649 581 463 347
Total Current Assets		 288 545 413 300 249
Cash & Equivalents		 202 401 158 66 41
Short-Term Investments		 51 91 217 160 188
Accounts Receivable		 16 33 19 56 4.64
Prepaid Expenses		 20 19 19 19 15
Plant, Property, & Equipment, net		 23 25 20 18 16
Total Noncurrent Assets		 78 79 148 145 82
Long-Term Investments		 0.89 0.89 82 98 42
Goodwill		 12 12 12 12 12
Intangible Assets		 21 26 25 4.58 1.35
Noncurrent Deferred & Refundable Income Taxes		 3.07 1.35 3.62 4.39 4.71
Other Noncurrent Operating Assets		 41 39 25 26 22
Total Liabilities & Shareholders' Equity		 389 649 581 463 347
Total Liabilities		 140 156 116 124 78
Total Current Liabilities		 72 96 56 88 42
Accounts Payable		 63 87 46 60 36
Current Deferred Revenue		 0.00 2.35 3.70 26 2.42
Current Deferred & Payable Income Tax Liabilities		 0.00 0.84 1.81 0.13 0.08
Other Current Liabilities		 9.06 4.96 4.26 2.74 3.47
Total Noncurrent Liabilities		 68 60 60 36 36
Noncurrent Deferred Revenue		 33 31 33 15 15
Noncurrent Deferred & Payable Income Tax Liabilities		 1.57 1.79 3.30 4.76 6.03
Other Noncurrent Operating Liabilities		 34 28 24 17 15
Total Equity & Noncontrolling Interests		 249 493 465 339 269
Total Preferred & Common Equity		 249 493 465 339 269
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 249 493 465 339 269
Common Stock		 939 1,038 1,140 1,168 1,220
Retained Earnings		 -683 -559 -677 -830 -953
Accumulated Other Comprehensive Income / (Loss)		 -6.66 -6.66 -6.60 -6.95 -6.08
Other Equity Adjustments		 0.00 20 9.35 8.19 7.94

Quarterly Balance Sheets for Zymeworks

This table presents Zymeworks' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 300 601 602 556 554 516 487 426 408 397 478
Total Current Assets		 191 426 420 375 394 383 344 306 296 292 386
Cash & Equivalents		 96 182 142 94 115 71 122 76 98 65 244
Short-Term Investments		 70 159 198 201 230 259 175 189 183 187 120
Accounts Receivable		 6.73 67 49 67 31 32 24 25 2.63 29 4.67
Prepaid Expenses		 18 19 31 12 18 21 23 17 12 10 16
Plant, Property, & Equipment, net		 26 24 22 21 19 18 18 17 16 16 15
Total Noncurrent Assets		 84 151 159 161 141 114 125 102 96 90 78
Long-Term Investments		 0.89 72 92 96 75 66 78 56 52 47 39
Goodwill		 12 12 12 12 12 12 12 12 12 12 12
Intangible Assets		 27 26 25 26 25 7.45 6.58 3.36 2.05 1.40 1.17
Noncurrent Deferred & Refundable Income Taxes		 3.03 1.41 1.36 1.32 3.70 3.95 4.21 4.85 4.77 4.86 4.71
Other Noncurrent Operating Assets		 41 39 29 26 25 24 25 26 25 24 21
Total Liabilities & Shareholders' Equity		 300 601 602 556 554 516 487 426 408 397 478
Total Liabilities		 121 127 153 132 116 109 120 101 74 77 315
Total Current Liabilities		 58 67 94 73 57 55 84 65 39 42 36
Accounts Payable		 52 59 70 68 47 44 52 38 31 34 30
Current Deferred Revenue		 - 2.35 18 0.09 3.44 5.52 27 23 3.81 3.20 2.08
Current Deferred & Payable Income Tax Liabilities		 - 0.84 1.16 0.83 1.86 1.93 2.07 0.13 0.10 1.02 0.07
Other Current Liabilities		 5.44 4.88 4.71 4.13 4.16 2.84 2.94 3.26 3.59 3.40 3.28
Total Noncurrent Liabilities		 63 60 60 59 59 55 36 35 35 35 279
Noncurrent Deferred Revenue		 33 31 31 33 33 33 15 15 15 15 15
Noncurrent Deferred & Payable Income Tax Liabilities		 1.59 1.86 1.92 1.97 3.35 3.40 3.46 4.82 4.85 4.77 3.83
Other Noncurrent Operating Liabilities		 28 27 27 24 23 18 18 16 16 16 261
Total Equity & Noncontrolling Interests		 180 474 449 424 438 406 367 325 335 320 164
Total Preferred & Common Equity		 180 474 449 424 438 406 367 325 335 320 164
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 180 474 449 424 438 406 367 325 335 320 164
Common Stock		 1,055 1,053 1,082 1,086 1,147 1,153 1,163 1,176 1,183 1,204 1,236
Retained Earnings		 -868 -583 -634 -663 -709 -747 -798 -853 -851 -886 -1,074
Accumulated Other Comprehensive Income / (Loss)		 -6.66 -5.94 -7.81 -8.30 -7.72 -7.90 -6.00 -6.41 -6.34 -6.05 -6.57
Other Equity Adjustments		 - 9.43 9.35 9.35 8.19 8.19 8.19 8.18 8.18 8.17 7.91

Annual Metrics And Ratios for Zymeworks

This table displays calculated financial ratios and metrics derived from Zymeworks' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - 74,836,534.00
DEI Adjusted Shares Outstanding		 - - - - - 74,836,534.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -1.07
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -131 -151 120 -97 -96 -65
Return On Investment Capital (ROIC_SIMPLE)		 - - 24.35% -20.79% -28.33% -24.13%
Earnings before Interest and Taxes (EBIT)		 -186 -214 132 -139 -137 -93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -176 -205 144 -122 -125 -82
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -147 116 -105 -102 -48
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 -4.40 -0.16 8.55 15 -2.08
Increase / (Decrease) in Invested Capital		 0.00 -4.40 4.24 8.71 6.02 -17
Book Value per Share		 $0.00 $4.83 $7.56 $6.64 $4.92 $3.59
Tangible Book Value per Share		 $0.00 $4.18 $6.97 $6.11 $4.68 $3.41
Total Capital		 0.00 249 493 465 339 269
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -253 -493 -456 -324 -271
Capital Expenditures (CapEx)		 4.31 12 8.15 2.47 1.99 1.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -36 -43 -17 -14 -22
Debt-free Net Working Capital (DFNWC)		 0.00 216 449 357 212 206
Net Working Capital (NWC)		 0.00 216 449 357 212 206
Net Nonoperating Expense (NNE)		 49 61 -4.33 22 27 16
Net Nonoperating Obligations (NNO)		 0.00 -253 -493 -456 -324 -271
Total Depreciation and Amortization (D&A)		 10 9.58 12 17 11 11
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $1.91 ($1.72) ($1.62) ($1.08)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 65.19M 68.86M 75.85M 75.40M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $1.90 ($1.72) ($1.62) ($1.08)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 65.25M 68.86M 75.88M 75.41M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 64.04M 70.57M 69.58M 73.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -131 -151 120 -97 -84 -65
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Zymeworks

This table displays calculated financial ratios and metrics derived from Zymeworks' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 74,836,534.00 73,749,607.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 74,836,534.00 73,749,607.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.55 -0.60
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 527.37% -95.79% -71.81% 174.82% -3.07% 83.33% 170.29% 153.21% 72.59% - -91.12%
EBITDA Growth		 44.32% -106.51% -41.49% 19.20% -21.80% 13.02% 36.74% 104.77% 39.49% - -98.23%
EBIT Growth		 33.46% -107.61% -35.04% 21.26% -5.54% 9.81% 31.83% 96.97% 36.66% - -83.84%
NOPAT Growth		 34.00% -105.32% -38.57% 20.75% -2.91% 5.14% 32.24% 97.56% 35.36% - -83.96%
Net Income Growth		 40.04% -104.68% -29.98% 26.33% -4.05% -62.31% 28.49% 106.15% 34.33% - -95.10%
EPS Growth		 43.06% -103.77% -13.51% 35.53% 4.88% -77.78% 28.57% 106.12% 33.33% - -96.67%
Operating Cash Flow Growth		 41.56% -95.74% 54.72% -290.53% 86.23% -397.46% 90.96% 148.31% -434.22% - -1,241.88%
Free Cash Flow Firm Growth		 0.00% 0.00% 120.54% 56.59% 130.44% 14.10% -123.18% 135.34% -356.08% - 5,673.48%
Invested Capital Growth		 0.00% 5,377.16% -70.96% -38.41% -123.72% 70.36% -80.83% -88.93% 362.44% - -7,258.94%
Revenue Q/Q Growth		 135.73% 2.54% -40.74% 91.85% -16.85% 93.94% -12.64% 79.73% -43.33% - -4.25%
EBITDA Q/Q Growth		 47.67% 19.79% -68.31% -14.37% 21.11% 42.72% -22.41% 108.62% -1,101.09% - -3.95%
EBIT Q/Q Growth		 39.98% 25.61% -54.61% -14.06% 19.55% 36.43% -16.87% 94.93% -1,583.01% - -5.72%
NOPAT Q/Q Growth		 38.58% 29.53% -61.40% -13.45% 20.24% 35.05% -15.29% 95.91% -2,011.95% - -6.72%
Net Income Q/Q Growth		 43.92% 49.52% -118.57% -19.06% 20.79% 21.25% 3.70% 110.24% -946.01% - -7.17%
EPS Q/Q Growth		 46.05% 56.10% -133.33% -16.67% 20.41% 17.95% 6.25% 110.00% -966.67% - -7.27%
Operating Cash Flow Q/Q Growth		 -566.78% 132.70% -369.95% 33.66% 76.48% -606.28% 91.79% 454.36% -360.18% - -345.64%
Free Cash Flow Firm Q/Q Growth		 -3.77% 55.59% 165.52% -245.02% 172.78% -225.32% 82.48% 321.14% -627.33% - 1,577.11%
Invested Capital Q/Q Growth		 100.45% -74.30% 110.13% -41.61% -177.18% 284.61% -76.96% -66.30% 1,730.59% - -11,434.04%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 -157.90% -123.51% -350.81% -209.13% -198.41% -58.60% -82.11% 3.94% -69.57% - -1,832.43%
Operating Margin		 -201.36% -138.37% -376.89% -222.87% -213.78% -71.60% -94.48% -1.38% -80.07% - -1,956.73%
EBIT Margin		 -197.52% -143.29% -373.86% -222.27% -215.06% -70.49% -94.30% -2.66% -78.93% - -1,951.74%
Profit (Net Income) Margin		 -173.80% -85.56% -315.58% -195.84% -186.56% -75.75% -83.50% 4.76% -70.99% - -1,833.97%
Tax Burden Percent		 104.03% 75.41% 100.24% 100.18% 100.76% 132.12% 102.24% 108.73% 107.31% - 95.27%
Interest Burden Percent		 84.58% 79.18% 84.21% 87.95% 86.09% 81.34% 86.61% -164.56% 83.81% - 98.63%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.73% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 -3,911.83% -1,755.72% -342.34% -729.59% -733.63% -330.91% -592.07% -32.56% -1,176.33% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -3,909.05% -1,756.12% -341.10% -727.74% -732.08% -328.87% -590.80% -33.39% -1,175.11% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 3,602.63% 1,740.74% 311.99% 704.92% 708.61% 319.41% 574.65% 32.88% 1,153.19% - 0.00%
Return on Equity (ROE)		 -309.20% -14.98% -30.35% -24.67% -25.02% -11.50% -17.42% 0.32% -23.14% - -42.02%
Cash Return on Invested Capital (CROIC)		 0.00% -1,232.29% -157.46% -669.51% 0.00% -882.55% -702.66% -859.87% -376.85% - 0.00%
Operating Return on Assets (OROA)		 -163.87% -17.72% -32.68% -24.94% -25.64% -10.30% -17.98% -0.71% -24.00% - -351.00%
Return on Assets (ROA)		 -144.19% -10.58% -27.59% -21.97% -22.24% -11.07% -15.92% 1.26% -21.59% - -329.82%
Return on Common Equity (ROCE)		 -309.20% -14.98% -30.35% -24.67% -25.02% -11.50% -17.42% 0.32% -23.14% - -42.02%
Return on Equity Simple (ROE_SIMPLE)		 48.37% 0.00% -28.76% -27.70% -30.97% 0.00% -34.98% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -23 -16 -26 -30 -24 -16 -18 -0.73 -15 -31 -33
NOPAT Margin		 -140.95% -96.86% -263.82% -156.01% -149.65% -50.12% -66.13% -1.50% -56.05% - -1,369.71%
Net Nonoperating Expense Percent (NNEP)		 -2.77% 0.40% -1.25% -1.85% -1.54% -2.04% -1.27% 0.84% -1.22% - -3.08%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.53% - - - -4.59% -5.52% -0.22% -4.84% -11.51% -20.16%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 102.80% 87.58% 157.43% 81.48% 86.58% 52.16% 62.65% 30.68% 51.23% - 625.79%
R&D to Revenue		 198.56% 150.80% 319.46% 241.39% 227.21% 63.73% 131.83% 70.70% 128.84% - 1,430.94%
Operating Expenses to Revenue		 301.36% 238.37% 476.89% 322.87% 313.78% 171.60% 194.48% 101.38% 180.07% - 2,056.73%
Earnings before Interest and Taxes (EBIT)		 -33 -24 -37 -43 -34 -22 -26 -1.30 -22 -44 -47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 -21 -35 -40 -32 -18 -22 1.92 -19 -42 -44
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.94 1.41 1.51 1.32 2.15 2.72 2.31 2.36 3.36 - 9.64
Price to Tangible Book Value (P/TBV)		 1.03 1.53 1.65 1.39 2.27 2.86 2.42 2.47 3.51 - 10.49
Price to Revenue (P/Rev)		 0.87 8.61 13.13 8.55 12.71 12.09 8.03 6.43 8.00 - 19.41
Price to Earnings (P/E)		 1.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 50.98% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.25 23.19 13.84 13.71 0.00 41.06 127.73 404.27 37.51 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.02 2.61 4.80 2.24 6.68 7.84 4.59 3.72 5.77 - 14.44
Enterprise Value to EBITDA (EV/EBITDA)		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 7.17
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -0.92 -0.99 -0.91 -0.97 -0.97 -0.97 -0.97 -0.98 -0.98 - -1.48
Leverage Ratio		 1.31 1.28 1.27 1.31 1.32 1.30 1.28 1.25 1.29 - 1.85
Compound Leverage Factor		 1.11 1.02 1.07 1.15 1.14 1.06 1.11 -2.05 1.08 - 1.82
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 1.43 2.48 2.24 1.52 2.19 2.50 2.37 4.55 6.15 - 0.59
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.14 7.41 6.92 7.01 4.10 3.40 4.71 7.69 6.94 - 10.82
Quick Ratio		 4.98 7.06 6.61 6.62 3.82 3.19 4.45 7.38 6.69 - 10.36
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -57 -25 16 -24 17 -22 -3.78 8.36 -44 -14 211
Operating Cash Flow to CapEx		 -4,587.85% 3,919.66% -20,361.62% -4,214.17% -653.73% -13,219.11% -21,293.75% 2,348.83% -7,661.46% - -21,165.74%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 101.95
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - -22.13
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - -22.23
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.83 0.12 0.09 0.11 0.12 0.15 0.19 0.27 0.30 - 0.18
Accounts Receivable Turnover		 6.86 2.88 1.03 1.55 1.37 2.03 3.36 7.08 5.07 - 5.55
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 22.08 3.41 2.38 3.07 3.17 4.07 5.24 7.06 7.88 - 5.15
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 53.20 126.95 353.92 235.46 266.94 180.08 108.55 51.56 72.00 - 65.73
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 53.20 126.95 353.92 235.46 266.94 180.08 108.55 51.56 72.00 - 65.73
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 33 8.55 18 10 -7.89 15 3.36 1.13 21 -2.08 -240
Invested Capital Turnover		 27.75 18.13 1.30 4.68 4.90 6.60 8.95 21.65 20.99 - -0.69
Increase / (Decrease) in Invested Capital		 33 8.71 -43 -6.37 -41 6.02 -14 -9.09 29 -17 -244
Enterprise Value (EV)		 8.32 198 242 140 416 598 429 457 777 - 1,174
Market Capitalization		 399 655 663 536 791 922 750 791 1,076 - 1,577
Book Value per Share		 $6.26 $6.64 $6.21 $5.74 $5.17 $4.92 $4.67 $4.80 $4.26 $3.59 $2.22
Tangible Book Value per Share		 $5.70 $6.11 $5.68 $5.47 $4.90 $4.68 $4.45 $4.60 $4.08 $3.41 $2.04
Total Capital		 424 465 438 406 367 339 325 335 320 269 164
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -391 -456 -420 -396 -375 -324 -322 -333 -299 -271 -404
Capital Expenditures (CapEx)		 0.93 0.36 0.19 0.59 0.90 0.31 0.02 0.51 0.41 0.58 0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 6.38 -17 -8.12 -1.36 -37 -14 -24 -24 -2.26 -22 -15
Debt-free Net Working Capital (DFNWC)		 302 357 337 329 260 212 241 258 250 206 350
Net Working Capital (NWC)		 302 357 337 329 260 212 241 258 250 206 350
Net Nonoperating Expense (NNE)		 5.42 -1.91 5.19 7.67 5.91 7.95 4.71 -3.05 4.13 10 11
Net Nonoperating Obligations (NNO)		 -391 -456 -420 -396 -375 -324 -322 -333 -299 -271 -404
Total Depreciation and Amortization (D&A)		 6.54 3.35 2.31 2.53 2.66 3.69 3.31 3.21 2.58 2.01 2.87
Debt-free, Cash-free Net Working Capital to Revenue		 1.38% -22.58% -16.08% -2.18% -60.03% -17.85% -25.62% -19.33% -1.68% - -18.08%
Debt-free Net Working Capital to Revenue		 65.38% 469.88% 667.66% 524.33% 417.79% 278.04% 258.46% 209.68% 185.65% - 430.74%
Net Working Capital to Revenue		 65.38% 469.88% 667.66% 524.33% 417.79% 278.04% 258.46% 209.68% 185.65% - 430.74%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.41) ($0.19) ($0.42) ($0.49) ($0.39) ($0.32) ($0.30) $0.03 ($0.26) ($0.55) ($0.59)
Adjusted Weighted Average Basic Shares Outstanding		 70.58M 68.86M 76.21M 76.39M 76.13M 75.85M 75.17M 75.34M 75.77M 75.40M 74.67M
Adjusted Diluted Earnings per Share		 ($0.41) ($0.18) ($0.42) ($0.49) ($0.39) ($0.32) ($0.30) $0.03 ($0.26) ($0.55) ($0.59)
Adjusted Weighted Average Diluted Shares Outstanding		 70.58M 68.86M 76.25M 76.40M 76.16M 75.88M 75.23M 77.38M 75.78M 75.41M 74.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 70.00M 70.57M 70.70M 71.05M 68.88M 69.58M 69.68M 75.17M 74.84M 73.75M 73.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -16 -26 -30 -24 -16 -18 -0.47 -15 -31 -33
Normalized NOPAT Margin		 -140.95% -96.86% -263.82% -156.01% -149.65% -50.12% -66.13% -0.97% -56.05% - -1,369.71%
Pre Tax Income Margin		 -167.07% -113.46% -314.84% -195.49% -185.15% -57.33% -81.67% 4.37% -66.15% - -1,924.96%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - -22.75
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - -15.96
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - -22.85
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - -16.07
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -24.49% 0.00% 0.00% -40.43% - -114.80%

Financials Breakdown Chart

Key Financial Trends

Here are notable trends for Zymeworks (NASDAQ: ZYME) using the quarterly cash flow, income statement, and balance sheet data from the last four years. The focus is on where the company has shown liquidity, profitability, and balance-sheet changes that may matter to retail investors.

  • Q2 2025: Net cash from continuing operating activities turned positive, at about $12.1 million, marking a rare positive quarterly operating cash flow in the period.
  • Q3 2025: Net cash from investing activities posted a small inflow (about $0.37 million), with a substantial $35.8 million inflow from sale/maturity of investments, suggesting liquidity support from asset dispositions.
  • Q4 2025: Net cash from continuing investing activities delivered a modest inflow (~$5.37 million), aided by ongoing investment-related activity.
  • Revenue and earnings have been volatile over the period, with quarterly operating revenue typically in the tens of millions but with swings that reflect changing contract activity and R&D timing.
  • Cash and equivalents have varied meaningfully across quarters in 2025, generally hovering in the $60–100 million range, implying a liquidity cushion but no sustained trend upward or downward.
  • Total assets have remained substantial (roughly in the $400–500 million range) and total equity has remained a large share of financing (roughly $320–$360 million), indicating a solid equity base despite volatility in cash flow.
  • Net income has largely been negative across most quarters (e.g., Q4 2025 net income continuing operations around -$41.2 million; Q3 2025 around -$19.6 million), highlighting ongoing profitability pressures.
  • Operating cash flow has been negative in most quarters (e.g., Q3 2025 around -$31.4 million; Q4 2025 around -$10.3 million), underscoring ongoing cash-burn from core operations.
  • Financing outflows were common in several periods (for example, Q4 2025 net cash from financing activities about -$18.7 million), indicating reliance on external financing or equity activity rather than self-generated cash.
  • Total liabilities have fluctuated and, at times, increased notably (e.g., rising toward approximately $120.6 million by early 2025), signaling higher leverage or accumulated obligations vs. prior periods.

Bottom line: ZYME shows occasional liquidity improvements driven by investing activity and modest equity financings, but continues to grapple with negative net income and cash flow from operations in many quarters. The balance sheet remains solid in terms of equity, but rising liabilities during parts of the period point to ongoing leverage and funding needs to support its R&D and operating activities. Retail investors should view the company as leveraging external financing and asset dispositions to fund operations, rather than generating stable, ongoing profitability from core activities.

05/21/26 01:53 PM ETAI Generated. May Contain Errors.

Zymeworks Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Zymeworks' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Zymeworks' net income appears to be on a downward trend, with a most recent value of -$81.13 million in 2025, falling from -$180.55 million in 2020. The previous period was -$122.70 million in 2024. Check out Zymeworks' forecast to explore projected trends and price targets.

Zymeworks' total operating income in 2025 was -$92.55 million, based on the following breakdown:
  • Total Gross Profit: $105.97 million
  • Total Operating Expenses: $198.51 million

Over the last 5 years, Zymeworks' total revenue changed from $38.95 million in 2020 to $105.97 million in 2025, a change of 172.0%.

Zymeworks' total liabilities were at $78.03 million at the end of 2025, a 37.2% decrease from 2024, and a 44.3% decrease since 2021.

In the past 4 years, Zymeworks' cash and equivalents has ranged from $41.16 million in 2025 to $400.91 million in 2022, and is currently $41.16 million as of their latest financial filing in 2025.

Over the last 5 years, Zymeworks' book value per share changed from 0.00 in 2020 to 3.59 in 2025, a change of 358.8%.


Related Companies

Financial statements for NASDAQ:ZYME last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel